Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
Enliven remains on track to initiate ENABLE-2 before year-end 2026 BURLINGAME, Calif., Oct. 6, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule...
Covered in this story
Analyst targets on Enliven Therapeutics Inc
- Morgan Stanley: $47 → $70 by Oct 2027 · Overweight via Investing.com
- JPMorgan: $46.2 → $75 by Oct 2027 · Overweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ELVN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Enliven Therapeutics Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.